Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.

Pseudohypoaldosteronism type 1 (PHA1) is a rare inherited disease characterized by resistance to the actions of aldosterone. Mutations in the subunit genes (SCNN1A, SCNN1B, SCNN1G) of the epithelial sodium channel (ENaC) and the NR3C2 gene encoding the mineralocorticoid receptor, result in systemic...

Full description

Bibliographic Details
Main Authors: Jian Wang, Tingting Yu, Lei Yin, Jing Li, Li Yu, Ye Shen, Yongguo Yu, Yongnian Shen, Qihua Fu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3675083?pdf=render
id doaj-341594c13dce479c8713f20ea2f77e03
record_format Article
spelling doaj-341594c13dce479c8713f20ea2f77e032020-11-24T21:41:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0186e6567610.1371/journal.pone.0065676Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.Jian WangTingting YuLei YinJing LiLi YuYe ShenYongguo YuYongnian ShenQihua FuPseudohypoaldosteronism type 1 (PHA1) is a rare inherited disease characterized by resistance to the actions of aldosterone. Mutations in the subunit genes (SCNN1A, SCNN1B, SCNN1G) of the epithelial sodium channel (ENaC) and the NR3C2 gene encoding the mineralocorticoid receptor, result in systemic PHA1 and renal PHA1 respectively. Common clinical manifestations of PHA1 include salt wasting, hyperkalaemia, metabolic acidosis and elevated plasma aldosterone levels in the neonatal period. In this study, we describe the clinical and biochemical manifestations in two Chinese patients with systemic PHA1. Sequence analysis of the SCNN1A gene revealed a compound heterozygous mutation (c.1311delG and c.1439+1G>C) in one patient and a homozygous mutation (c.814_815insG) in another patient, all three variants are novel. Further analysis of the splicing pattern in a minigene construct showed that the c.1439+1G>C mutation can lead to the retainment of intron 9 as the 5'-donor splice site disappears during post-transcriptional processing of mRNA. In conclusion, our study identified three novel SCNN1A gene mutations in two Chinese patients with systemic PHA1.http://europepmc.org/articles/PMC3675083?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jian Wang
Tingting Yu
Lei Yin
Jing Li
Li Yu
Ye Shen
Yongguo Yu
Yongnian Shen
Qihua Fu
spellingShingle Jian Wang
Tingting Yu
Lei Yin
Jing Li
Li Yu
Ye Shen
Yongguo Yu
Yongnian Shen
Qihua Fu
Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.
PLoS ONE
author_facet Jian Wang
Tingting Yu
Lei Yin
Jing Li
Li Yu
Ye Shen
Yongguo Yu
Yongnian Shen
Qihua Fu
author_sort Jian Wang
title Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.
title_short Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.
title_full Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.
title_fullStr Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.
title_full_unstemmed Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.
title_sort novel mutations in the scnn1a gene causing pseudohypoaldosteronism type 1.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Pseudohypoaldosteronism type 1 (PHA1) is a rare inherited disease characterized by resistance to the actions of aldosterone. Mutations in the subunit genes (SCNN1A, SCNN1B, SCNN1G) of the epithelial sodium channel (ENaC) and the NR3C2 gene encoding the mineralocorticoid receptor, result in systemic PHA1 and renal PHA1 respectively. Common clinical manifestations of PHA1 include salt wasting, hyperkalaemia, metabolic acidosis and elevated plasma aldosterone levels in the neonatal period. In this study, we describe the clinical and biochemical manifestations in two Chinese patients with systemic PHA1. Sequence analysis of the SCNN1A gene revealed a compound heterozygous mutation (c.1311delG and c.1439+1G>C) in one patient and a homozygous mutation (c.814_815insG) in another patient, all three variants are novel. Further analysis of the splicing pattern in a minigene construct showed that the c.1439+1G>C mutation can lead to the retainment of intron 9 as the 5'-donor splice site disappears during post-transcriptional processing of mRNA. In conclusion, our study identified three novel SCNN1A gene mutations in two Chinese patients with systemic PHA1.
url http://europepmc.org/articles/PMC3675083?pdf=render
work_keys_str_mv AT jianwang novelmutationsinthescnn1agenecausingpseudohypoaldosteronismtype1
AT tingtingyu novelmutationsinthescnn1agenecausingpseudohypoaldosteronismtype1
AT leiyin novelmutationsinthescnn1agenecausingpseudohypoaldosteronismtype1
AT jingli novelmutationsinthescnn1agenecausingpseudohypoaldosteronismtype1
AT liyu novelmutationsinthescnn1agenecausingpseudohypoaldosteronismtype1
AT yeshen novelmutationsinthescnn1agenecausingpseudohypoaldosteronismtype1
AT yongguoyu novelmutationsinthescnn1agenecausingpseudohypoaldosteronismtype1
AT yongnianshen novelmutationsinthescnn1agenecausingpseudohypoaldosteronismtype1
AT qihuafu novelmutationsinthescnn1agenecausingpseudohypoaldosteronismtype1
_version_ 1725919940108615680